Last reviewed · How we verify
Baricitinib Oral Tablet [Olumiant] — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Baricitinib Oral Tablet [Olumiant] (Baricitinib Oral Tablet [Olumiant]) — Assistance Publique - Hôpitaux de Paris.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Baricitinib Oral Tablet [Olumiant] TARGET | Baricitinib Oral Tablet [Olumiant] | Assistance Publique - Hôpitaux de Paris | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Baricitinib Oral Tablet [Olumiant] CI watch — RSS
- Baricitinib Oral Tablet [Olumiant] CI watch — Atom
- Baricitinib Oral Tablet [Olumiant] CI watch — JSON
- Baricitinib Oral Tablet [Olumiant] alone — RSS
Cite this brief
Drug Landscape (2026). Baricitinib Oral Tablet [Olumiant] — Competitive Intelligence Brief. https://druglandscape.com/ci/baricitinib-oral-tablet-olumiant. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab